INSYS THERAPEUTICS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2001-09-25

Last Posted Date: 2011-04-13

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 30

Registration Number: NCT00024661

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses

Phase 1

Withdrawn

Conditions: Neoplasms

First Posted Date: 2001-09-25

Last Posted Date: 2014-11-14

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT00024687

Locations: 🇺🇸
NCI/NIH, Bethesda, Maryland, United States

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Phase 1

Completed

Conditions: Malignant Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Mixed Oligoastrocytoma
Malignant Astrocytoma

First Posted Date: 2001-09-21

Last Posted Date: 2011-06-06

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT00024557

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 1 locations

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Anaplastic Astrocytoma
Glioblastoma Multiforme
Mixed Oligoastrocytoma
Malignant Glioma

First Posted Date: 2001-09-21

Last Posted Date: 2014-11-14

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 60

Registration Number: NCT00024570

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Henry Ford Health Systems, Detroit, Michigan, United States

and more 5 locations

Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Tumors

First Posted Date: 2001-09-18

Last Posted Date: 2011-06-06

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT00024492

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy